Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

Cell Death and Differentiation

Volumn 18, Issue 2, 2011, Pages 271-281

  Kogan Sakin, I ^a   Tabach, Y ^a   Buganim, Y ^a   Molchadsky, A ^a   Solomon, H ^a   Madar, S ^a   Kamer, I ^a   Stambolsky, P ^a   Shelly, A ^a   Goldfinger, N ^a   Valsesia Wittmann, S ^b   Puisieux, A ^b   Zundelevich, A ^c   Gal Yam, E N ^c   Avivi, C ^c   Barshack, I ^c   Brait, M ^d   Sidransky, D ^d   Domany, E ^a   Rotter, V ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b INSERM   (France)

^c SHEBA MEDICAL CENTER   (Israel)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

p53; prostate; Twist1

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR TWIST;

ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WILD TYPE;

AMINO ACID SUBSTITUTION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONES; HUMANS; MALE; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TWIST TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 78651289008     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.94     Document Type: Article

References (28)

1. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22: 9030-9040.
2. Vousden KH. p53: death star. Cell 2000;103: 691-694.
3. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1: 68-76.
4. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60: 6788-6793.
5. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001;277: 15-30.
6. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene 2007;26: 2202-2211.
7. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996;48: 971-979. (Pubitemid 127739005)
8. Zeng L, Rowland RG, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004;35: 290-297.
9. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G et al. hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res 2006;66: 3531-3540.
10. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002;51: 59-72.
11. Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A et al. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res 2003;63: 7147-7157.
12. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117: 927-939.
13. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65: 5153-5162.
14. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE et al. The epithelial- mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancer(s). Urol Oncol 2009, in press (e-pub ahead of print 9 March 2009).
15. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30: 256-268.
16. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5: 675-688.
17. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447: 433-440.
18. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007;128: 669-681.
19. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119: 861-872.
20. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001;21: 1874-1887.
21. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010;5: 349-371.
22. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6: 2138-2145.
23. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10: 191-202.
24. Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK et al. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat 2009;113: 83-93.
25. Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2008;10: R109.
26. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 2000;25: 25-29.
27. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4: P3.
28. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004;64: 8318-8327.